Energenesis Biomedical CO.,LTD. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was TWD 2 million compared to TWD 1.47 million a year ago. Net loss was TWD 119.61 million compared to TWD 29.09 million a year ago. Basic loss per share from continuing operations was TWD 1.8 compared to TWD 0.49 a year ago.
For the nine months, sales was TWD 4.86 million compared to TWD 5.06 million a year ago. Net loss was TWD 219.96 million compared to TWD 82.98 million a year ago. Basic loss per share from continuing operations was TWD 3.3 compared to TWD 1.39 a year ago.